Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate.